- Price
- $89.60
- Day
- +0.88%
- Mkt Cap
- $51.59B
- 52W Range
- $72.30 – $96.29
- Volume
- 4.07M
- Beta
- 0.85
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Glenmede Trust Co. NA trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 4.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 167,483 shares of the medical research company's stock after selling 6,923 shares
Read full article
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Read full article
Total Sales: $1.74 billion, a 12.5% increase year-over-year.Adjusted EPS: $0.78 for the quarter.TAVR Sales: $1.3 billion, a 10.5% increase over the prior year.
Read full article
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
Read full article
Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.
Read full article
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas.
Read full article
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript
Read full article
Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.
Read full article
Edwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.
Read full article
Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.
Read full article
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
Read full article
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article